| Id
|
Protein
|
PTM type
|
Site
|
Species
|
Disease
|
Celline
|
Drug
|
Regulatory
|
Score
|
Ref.
|
| acc0401 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Endometrial Cancer |
Ishikawa |
Cisplatin |
Enhancing |
5.0 |
25375375
|
| acc0402 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Hepatocellular Carcinoma |
HepG2 |
Cisplatin |
Enhancing |
5.0 |
25375375
|
| acc0403 |
ERK1 |
phosphorylation |
Thr202 |
human |
Endometrial Cancer |
Ishikawa |
Bortezomib |
Associated |
4.0 |
25375375
|
| acc0404 |
ERK1 |
phosphorylation |
Thr202 |
human |
Hepatocellular Carcinoma |
HepG2 |
Bortezomib |
Associated |
4.0 |
25375375
|
| acc0405 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Ovarian Cancer |
TOV112D |
Bortezomib |
Associated |
4.0 |
25375375
|
| acc0406 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Ovarian Cancer |
TOV21G |
Bortezomib |
Associated |
4.0 |
25375375
|
| acc0407 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Endometrial Cancer |
Ishikawa |
Bortezomib |
Associated |
4.0 |
25375375
|
| acc0408 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Hepatocellular Carcinoma |
HepG2 |
Bortezomib |
Associated |
4.0 |
25375375
|
| acc0409 |
ERK1 |
phosphorylation |
Thr202 |
human |
Ovarian Cancer |
TOV112D |
Cisplatin |
Enhancing |
5.0 |
25375375
|
| acc0410 |
ERK1 |
phosphorylation |
Thr202 |
human |
Ovarian Cancer |
TOV21G |
Cisplatin |
Enhancing |
5.0 |
25375375
|
| acc0411 |
Src |
phosphorylation |
Tyr416 |
human |
Gastric Cancer |
SGC7901 |
Cetuximab |
Impairing |
5.0 |
25625229
|
| acc0412 |
Src |
phosphorylation |
Tyr416 |
human |
Gastric Cancer |
MGC803 |
Cetuximab |
Impairing |
5.0 |
25625229
|
| acc0413 |
IGF-IR |
phosphorylation |
Tyr1131 |
human |
Gastric Cancer |
SGC7901 |
Cetuximab |
Impairing |
5.0 |
25625229
|
| acc0414 |
IGF-IR |
phosphorylation |
Tyr1131 |
human |
Gastric Cancer |
MGC803 |
Cetuximab |
Impairing |
5.0 |
25625229
|
| acc0415 |
AKT |
phosphorylation |
Ser473 |
human |
Gastric Cancer |
SGC7901 |
Cetuximab |
Impairing |
5.0 |
25625229
|
| acc0416 |
AKT |
phosphorylation |
Ser473 |
human |
Gastric Cancer |
MGC803 |
Cetuximab |
Impairing |
5.0 |
25625229
|
| acc0417 |
IGF-IR |
phosphorylation |
Tyr1131 |
human |
Gastric Cancer |
SGC7901 |
Cetuximab |
Impairing |
5.0 |
25625229
|
| acc0418 |
IGF-IR |
phosphorylation |
Tyr1131 |
human |
Gastric Cancer |
MGC803 |
Cetuximab |
Impairing |
5.0 |
25625229
|
| acc0419 |
STAT1 |
phosphorylation |
Tyr701 |
human |
Pancreas Cancer |
SW1990 |
Gemcitabine |
Enhancing |
5.0 |
30782607
|
| acc0420 |
STAT1 |
phosphorylation |
Tyr701 |
human |
Prostate Cancer |
BxPC3 |
Gemcitabine |
Enhancing |
5.0 |
30782607
|
| acc0421 |
MEK |
phosphorylation |
Ser217 |
human |
Ovarian Cancer |
MCAS |
Navitoclax |
Enhancing |
5.0 |
25968887
|
| acc0422 |
MEK |
phosphorylation |
Ser217 |
human |
Ovarian Cancer |
OVCAR8 |
Navitoclax |
Enhancing |
5.0 |
25968887
|
| acc0423 |
ERK1 |
phosphorylation |
Thr202 |
human |
Ovarian Cancer |
MCAS |
Trametinib |
Enhancing |
5.0 |
25968887
|
| acc0424 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Ovarian Cancer |
MCAS |
Trametinib |
Enhancing |
5.0 |
25968887
|
| acc0425 |
ERK2 |
phosphorylation |
Thr185 |
human |
Ovarian Cancer |
MCAS |
Trametinib |
Enhancing |
5.0 |
25968887
|
| acc0426 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Ovarian Cancer |
MCAS |
Trametinib |
Enhancing |
5.0 |
25968887
|
| acc0427 |
MEK |
phosphorylation |
Ser221 |
human |
Ovarian Cancer |
MCAS |
Navitoclax |
Enhancing |
5.0 |
25968887
|
| acc0428 |
MEK |
phosphorylation |
Ser221 |
human |
Ovarian Cancer |
OVCAR8 |
Navitoclax |
Enhancing |
5.0 |
25968887
|
| acc0429 |
ERK1 |
phosphorylation |
Thr202 |
human |
Ovarian Cancer |
MCAS |
Navitoclax |
Enhancing |
5.0 |
25968887
|
| acc0430 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Ovarian Cancer |
MCAS |
Navitoclax |
Enhancing |
5.0 |
25968887
|
| acc0431 |
ERK2 |
phosphorylation |
Thr185 |
human |
Ovarian Cancer |
MCAS |
Navitoclax |
Enhancing |
5.0 |
25968887
|
| acc0432 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Ovarian Cancer |
MCAS |
Navitoclax |
Enhancing |
5.0 |
25968887
|
| acc0433 |
MEK |
phosphorylation |
Ser217 |
human |
Ovarian Cancer |
MCAS |
Trametinib |
Enhancing |
5.0 |
25968887
|
| acc0434 |
MEK |
phosphorylation |
Ser221 |
human |
Ovarian Cancer |
MCAS |
Trametinib |
Enhancing |
5.0 |
25968887
|
| acc0435 |
CSE1L |
phosphorylation |
unclear |
human |
Colorectal Cancer |
HT29 |
Vemurafenib + Sorafenib |
Associated |
4.0 |
26070816
|
| acc0436 |
ERK1 |
phosphorylation |
Thr202 |
human |
Colorectal Cancer |
HT29 |
Vemurafenib + Sorafenib |
Associated |
4.0 |
26070816
|
| acc0437 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Colorectal Cancer |
HT29 |
Vemurafenib + Sorafenib |
Associated |
4.0 |
26070816
|
| acc0438 |
ERK2 |
phosphorylation |
Thr185 |
human |
Colorectal Cancer |
HT29 |
Vemurafenib + Sorafenib |
Associated |
4.0 |
26070816
|
| acc0439 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Colorectal Cancer |
HT29 |
Vemurafenib + Sorafenib |
Associated |
4.0 |
26070816
|
| acc0440 |
CSE1L |
phosphorylation |
unclear |
human |
Melanoma |
A375 |
Vemurafenib + Sorafenib |
Associated |
4.0 |
26070816
|
| acc0441 |
ERK1 |
phosphorylation |
Thr202 |
human |
Melanoma |
A375 |
Vemurafenib + Sorafenib |
Associated |
4.0 |
26070816
|
| acc0442 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Melanoma |
A375 |
Vemurafenib + Sorafenib |
Associated |
4.0 |
26070816
|
| acc0443 |
ERK2 |
phosphorylation |
Thr185 |
human |
Melanoma |
A375 |
Vemurafenib + Sorafenib |
Associated |
4.0 |
26070816
|
| acc0444 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Melanoma |
A375 |
Vemurafenib + Sorafenib |
Associated |
4.0 |
26070816
|
| acc0445 |
AMPK |
phosphorylation |
Thr180 |
human |
Colorectal Cancer |
HT29 |
TPA |
Associated |
4.0 |
26116564
|
| acc0446 |
AMPK |
phosphorylation |
Thr180 |
human |
Colorectal Cancer |
SW620 |
TPA |
Associated |
4.0 |
26116564
|
| acc0447 |
AMPK |
phosphorylation |
Tyr182 |
human |
Colorectal Cancer |
HT29 |
TPA |
Associated |
4.0 |
26116564
|
| acc0448 |
AMPK |
phosphorylation |
Tyr182 |
human |
Colorectal Cancer |
SW620 |
TPA |
Associated |
4.0 |
26116564
|
| acc0449 |
Smad3 |
phosphorylation |
Ser423 |
human |
Hepatocellular Carcinoma |
HCC |
Sorafenib |
Enhancing |
5.0 |
26666823
|
| acc0450 |
Smad3 |
phosphorylation |
Ser425 |
human |
Hepatocellular Carcinoma |
HCC |
Sorafenib |
Enhancing |
5.0 |
26666823
|
